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a  b  s  t  r  a  c  t
High-throughput  analyses  of RNA  and  protein  expression  are  increasingly  used  for  better  understanding
of  vaccine-induced  immunity  and  protection  against  infectious  disease.  With  an  increasing  number  of
vaccine  candidates  in clinical  development,  it is  timely  to consider  standardisation  and harmonisation  of
sample  collection,  storage  and analysis  to  ensure  results  of  highest  quality  from  these  precious  samples.
These  challenges  were  discussed  by  a group  of  international  experts  during  a workshop  organised  by
TRANSVAC,  a  European  Commission-funded  Research  Infrastructure  project.  The  main  conclusions  were:
Platforms are  rarely  standardised  for use  in  preclinical  and  clinical  studies.  Coordinated  efforts  should
continue  to harmonise  the  experimental  set up  of these  studies,  as  well  as the  establishment  of  internal
standards  and  controls.  This  will  ensure  comparability,  efﬁciency  and  feasibility  of  the  global  analyses
performed  on preclinical  and  clinical  data  sets.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Abbreviations: dcRT-MLPA, dual colour reverse transcription multiplex ligation-dependent probe ampliﬁcation; EC, European Commission; ELISA, enzyme linked
immunosorbent assay; FP, Framework Programme; HIV, human immunodeﬁciency virus; HVTN, HIV Vaccine Trials Network; IMI, innovative medicines initiative; PBMC,
peripheral blood mononuclear cell; QA, quality assurance; QC, quality control; RNA, ribonucleic acid; RT-PCR, real-time polymerase chain reaction; SOP, standard operating
procedures; TB, tuberculosis.
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1. Introduction
Global molecular analyses are exploited to enhance our
understanding of novel vaccination strategies. High-throughput
technologies, including microarray analyses and RNA deep
sequencing, allow genome-wide proﬁling of gene expression
within different study groups. Similarly, targeted assays enable
study of the expression of a dedicated number of genes [e.g. dual
colour reverse transcription multiplex ligation-dependent probe
ampliﬁcation (dcRT-MLPA) assay], cell-expressed molecules (e.g.
ﬂow cytometry) or secreted molecules (multiplex assays).
Expectations of data output from these analyses in vaccine
trials are high, and it is hoped that through the systematic anal-
ysis of biomarkers using modern bioassays, predictive biomarkers,
which can be used as (surrogate) markers of clinical endpoints or
of adverse events, can be identiﬁed. In tuberculosis (TB), human
immunodeﬁciency virus (HIV), and malaria, few approaches are on
the pathway for use with clinical trial samples for prediction of both
vaccine efﬁcacy and vaccine safety. However, molecular analytical
tools are providing ﬁrst hints regarding mechanisms underlying
protection against, or susceptibility to, developing clinical disease
[1–3]. Since there are now a number of vaccine candidates in phase
II/III clinical trials in the TB, HIV, and malaria arenas, it is timely to
consider standardisation and harmonisation of sample collection,
storage and molecular analysis to ensure highest quality data from
these precious samples.
In order to discuss these challenges a workshop was organised
by TRANSVAC, a European Commission (EC)-funded project coordi-
nated by the European Vaccine Initiative. The aim of the workshop
was to deﬁne and implement a process supporting the harmonisa-
tion of operational procedures for the proﬁling and the assessment
of novel vaccine candidates, novel vaccine formulations, and/or
novel routes of administration. Through internal research activi-
ties in the ﬁeld of HIV, TB, and malaria, and through the supply of
services to 24 projects, including free access to adjuvants, animal
models, microarray analysis, and assays/standards, the TRANSVAC
partners have contributed to harmonisation of protocols. These
efforts, which took place between 2009 and 2013, were discussed
at the TRANSVAC workshop.
2. Overview from data sets obtained with different
technologies, diseases and species, and in different clinical
settings
2.1. Genome-wide high-throughput technologies
To obtain meaningful data sets from preclinical studies and
clinical trials, standardisation and harmonisation of sample collec-
tion, storage and analysis are crucial. Results performed with three
genome-wide high-throughput technologies (Agilent Technolo-
gies and Affymetrix transcriptome platforms, as well as Illumina
sequencing platform) were presented [4,5]. While sample collec-
tion and pre-processing of the samples (e.g. RNA isolation, labelling
for microarray analysis and library generation for sequencing) are
well standardised, analysis was confounded by different inﬂuences,
including the nonhuman primate sub-species analysed, the health
history of study participants, and by differences in the sources of
RNA (e.g. cell-free nucleic acids and platelet RNA, both derived from
different types of blood cells).
It was concluded that essential factors for studies involving
microarrays are (i) group sizes, (ii) timepoints of measure-
ment (including multiple pre-vaccination time points to account
for inter-individual variation), (iii) strength of vaccine-induced
responses, (iv) nature of test samples, and (v) quality of test sam-
ples.
Previous studies have found that, depending on sequencing
depth, next-generation sequencing platforms can be more com-
prehensive than microarrays in detecting expression differences
and have no hybridisation bias [6,7], but are computationally more
complex and time consuming. Nevertheless, computational bioin-
formatics’ analyses are essential for both techniques to obtain
meaningful data and to compare data sets, and can best be embed-
ded at the research group level [8,9].
2.2. Other technologies
Global analysis of metabolites (metabolomics) in serum has
proven its value for biomarker design in infectious diseases includ-
ing monitoring of vaccine trials [7].
Flow cytometric analysis and/or mass cytometric analysis of
cells or cell-bound proteins can be used as predictive biomarkers for
disease outcome and response to immune interventions [10]. These
approaches seem to be more powerful than conventional methods,
such as ELISA and Luminex, with key features like a short sample
processing time, low blood amounts required per condition to be
tested, the possibility to process both stimulated or non-stimulated
samples, and the use of fresh samples which reduces the artefacts
and loss of sensitivity due to cryopreservation. Important issues
to guarantee reliability of the obtained data are standardisation
of sample preparation, transport and storage, inter-test variation
(occurring when large numbers of samples are processed by a single
operator on a single day), data acquisition, and appropriate quality
controls (QCs) (e.g. acceptable percentage of dead cells, minimum
number of analysed events, reference controls). In the ﬁeld of can-
cer immunotherapy, harmonisation and standardisation of T-cell
immunoassays (e.g. ELISpot and intracellular cytokine staining) has
proven to be feasible on an international scale with great success
[11].
Growth inhibition assays are increasingly used in TB and
malaria. For TB, whole blood or PBMC-based tests utilising a liquid
culture system for detection of mycobacterial growth have shown
promise and are currently being assessed for use in early phase
vaccine clinical trials [12,13].
As an alternative to array-based platforms, assays have been
designed that offer speciﬁc, robust, affordable and practical bio-
proﬁling platforms. The dcRT-MLPA assay is a RT-PCR-based gene
expression proﬁling method, which represents a valid alternative to
perform intermediate sized multiplex screens [1,3] once a tailored
signature has been composed, e.g., based on information from unbi-
ased genome-wide expression analysis. The assay setup ensures
high assay sensitivity and avoids the limitations of multiplex PCR
and the costly aspects of genome-wide platforms such as micro-
arrays and RNA sequencing.
2.3. Integration of epidemiological data
It is becoming increasingly obvious that type of samples used
(e.g. whole blood, PBMC, serum, plasma and urine), age of the indi-
viduals, or environmental factors (e.g. the circadian rhythm of the
subjects including the number of sleep hours) can have a great
impact on host responses [14]. It is thus important to carefully mon-
itor epidemiological data from clinical trial study participants to
draw adequate conclusions, when analysing the data.
In the context of clinical trials, systems biology combines clin-
ical and epidemiological data with all transcriptional, proteomic,
metabolomic and immunological data gathered [8,9,15–19]. There
are three interlinking components of systems biology: experimen-
tal design, biological questions and data analysis. This results in
a data set that ultimately needs to be validated before it can be
usefully applied. Tools are available that can greatly reduce data
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complexity and help in the identiﬁcation of biomarkers, but over-
simpliﬁcation may  lead to loss of insight into pathomechanisms.
A major bottleneck remains the difﬁculty to sustain a highly
controlled environment in phase I clinical trials, during the time
period between vaccination and the expected “operation” time of
the vaccine. Moreover, to fully correct for all the parameters inﬂu-
encing the data, sampling schedules including a high number of
critically chosen samples and time points are needed, but are fre-
quently ignored due to time and cost restrictions. A trade-off thus
has to be found between the amount of data that can be obtained
and the means and know-how available to analyse the collected
data.
2.4. Comparison of data from different preclinical/clinical trials
A number of EC Framework Programme (FP) 6 and FP7 projects
(i.e. TBVAC/NEWTBVAC, ADITEC, Euroneut41, OPTIMALVAC and
EMVDA), and the IMI  project BioVacSafe have contributed to stan-
dardisation of different protocols and SOPs, in order to allow
comparison of readouts between different clinical trial sites. While
strict reporting forms are well advanced [20–22], bottlenecks are
time frame differences and investigator-speciﬁc protocols.
A different approach is to centralise all immunological read-
outs. The HIV Vaccine Trials Network (HVTN, Dr. Julie McElrath) is
the quintessential example of a centralised infrastructure driving
and executing the analysis of vaccine-induced immune responses
in large clinical trials. HVTN has centralised use of qualiﬁed and
validated immune assays, of common reagents, and of archived
specimens, as well as collaborations and infrastructures including
advanced planning. A centralised lead laboratory is responsible for
quality assurance (QA)/QC and the repository of samples, while spe-
cialised working groups take care of protocols, support and QC of
specimen [22]. Notable trials that were evaluated by HVTN were
the HIV-1 STEP and RV144 trials [23,24].
3. Recommendations and conclusions
Only few global analysis platforms are fully standardised to
inform and allow informative use in preclinical studies and clin-
ical trials through which licensure could be obtained. Coordinated
efforts between different disease networks should continue to
achieve standardisation of immunological and global platforms
that will allow their effective use in a clinical setting, their use for
biomarker discovery and validation, and their use in generating
data sets that can be compared between different platforms and
across different preclinical settings and/or different clinical trials.
The main challenges to be overcome when performing global
analyses can be grouped into the following:
I. Deﬁnition of study group sizes and numbers in order to compare
studies.
II. Recommendations for sample collection and storage for future
analysis wherever possible according to generally agreed-upon
recommendations.
III. Understanding of the inﬂuence of the environment on host
responses. Not all variables can be taken into account when
performing clinical studies and it is important to identify the
parameters of greatest inﬂuence and to harmonise their moni-
toring.
IV. Establishment of internal standards and controls to ensure
comparability, efﬁciency and feasibility of molecular and
immunological proﬁling.
These challenges require international collaboration, which
could be led by the Systems Biology Platform of the European
Vaccine Research and Development Infrastructure, in association
with regulatory agencies and representatives of the World Health
Organisation. The process of harmonising methodology, sample
and data collection, and the analysis of data will beneﬁt from pre-
vious experiences in ADITEC and BIOVACSAFE European projects,
together with the NIAID-sponsored Systems Biology for Infectious
Diseases Research Program. The working parties should agree
on core recommendations and a strategic action plan to address
these priorities. If funding for European Vaccine Research and
Development Infrastructure materialises in 2015, a pilot phase will
be launched for structuring global analyses of infectious diseases
with high public health importance, such as AIDS, tuberculosis,
malaria, and inﬂuenza.
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